Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas

Soham D. Puvvada, José Guillen-Rodriguez, Abhijeet Kumar, Lora Inclán, Kara Heard, Xavier I. Rivera, Faiz Anwer, Jonathan H. Schatz, Daruka Mahadevan, Daniel O. Persky

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science